Boston Scientific’s EKOS™ Endovascular System Demonstrates Superiority in Treating Acute Pulmonary Embolism: HI-PEITHO Trial Results
Key Highlights from the HI-PEITHO Global Randomized Clinical Trial
- Boston Scientific’s EKOS™ Endovascular System, combined with anticoagulation, demonstrated significant superiority over anticoagulation alone for the treatment of acute intermediate-risk pulmonary embolism (PE).
- The HI-PEITHO study met its composite primary endpoint, with a statistically significant reduction in clinical event rates for patients treated with the EKOS system.
- Data from the trial were simultaneously presented at ACC.26 (American College of Cardiology’s Annual Scientific Session & Expo) and published in The New England Journal of Medicine.
- Key efficacy finding: EKOS system plus anticoagulation reduced the primary endpoint events by 61% (4.0% vs. 10.3%, P=0.005) compared to anticoagulation alone.
- EKOS-treated patients also showed a lower rate of cardiorespiratory decompensation or collapse (3.7% vs. 10.3%) and had shorter hospital stays, with no increase in major bleeding or intracranial hemorrhage through 30 days.
- The trial enrolled 544 patients with intermediate-risk PE across 59 sites in the U.S. and Europe, with ongoing follow-up to one year post-procedure.
In-Depth Details and Implications for Investors
Pulmonary embolism (PE) is a serious, potentially fatal condition caused by blood clots blocking pulmonary arteries and is the third leading cause of cardiovascular mortality globally. Standard treatment has been anticoagulation for all risk levels, but minimally invasive interventions like the EKOS system are designed to improve outcomes by delivering clot-dissolving drugs directly to the clot using ultrasound energy.
The HI-PEITHO trial rigorously compared the EKOS system plus anticoagulation to anticoagulation alone in intermediate-risk PE patients. The results highlight a substantial reduction in the composite primary endpoint (PE-related mortality, non-fatal hemodynamic cardiorespiratory decompensation or collapse, and non-fatal symptomatic recurrence of PE within seven days).
Notably, the EKOS group experienced:
- 61% reduction in primary endpoint events (4.0% vs. 10.3%)
- Lower cardiorespiratory decompensation or collapse (3.7% vs. 10.3%)
- No increase in major bleeding or intracranial hemorrhage at 30 days
- Shorter hospital stays compared to standard care
Dr. Stavros Konstantinides, principal investigator, emphasized that these results provide clinicians with robust new data supporting the EKOS system as a first-line therapy option for intermediate-risk PE. This is the first time such outcome-driven, randomized trial data has been available for this intervention.
Potential Shareholder Impact and Price Sensitivity
- First robust randomized trial data supporting EKOS as first-line therapy: This positions Boston Scientific for potential growth in the PE intervention market, possibly influencing hospital adoption, guideline changes, and increased market share.
- No increase in bleeding risk: This addresses prior safety concerns that may have limited adoption.
- Shorter hospital stays: May translate to cost savings for healthcare systems, further supporting EKOS adoption.
- Strong clinical validation: Publication in a leading medical journal and presentation at a major conference boosts credibility and visibility.
- Ongoing follow-up: Investors should watch for one-year outcomes which could further impact market adoption and guideline recommendations.
These results could be highly price sensitive, as clinical trial success in a large, high-mortality disease area like PE can drive increased device sales, improved market positioning, and potentially higher share prices for Boston Scientific.
Additional Considerations for Investors
- Trial scale and rigor: 544 patients, 59 global sites, partnership with leading academic and clinical institutions, and ongoing follow-up to one year.
- Commercial and competitive impact: Data positions Boston Scientific to capture greater share in the PE intervention market, possibly displacing competitors who cannot demonstrate similar outcomes.
- Forward-looking statements and risks: The company cautions about risks including economic, competitive, regulatory, and supply chain factors that could affect future performance.
Company Background
Boston Scientific is a global leader in medical technologies, with a broad portfolio across cardiovascular, respiratory, digestive, oncological, neurological, and urological diseases. The EKOS system is part of its vascular therapies segment.
Contact Information
Disclaimer: This article is for informational purposes only. It is not investment advice. Investors should perform their own due diligence and consider all relevant risks, as described in Boston Scientific’s filings with the SEC, before making any investment decisions. All forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected.
View BOSTON SCIENTIFIC CORP Historical chart here
